MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
23.17
+1.97
+9.29%
After Hours: 22.81 -0.36 -1.55% 19:54 12/01 EST
OPEN
21.55
PREV CLOSE
21.20
HIGH
23.24
LOW
20.67
VOLUME
4.22M
TURNOVER
0
52 WEEK HIGH
42.48
52 WEEK LOW
20.67
MARKET CAP
2.48B
P/E (TTM)
-12.0489
1D
5D
1M
3M
1Y
5Y
Arrowhead Pharmaceuticals Earns ‘Buy’ Rating on Strong Clinical Pipeline and Strategic Growth Potential
TipRanks · 2d ago
Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed
Arrowhead pharmaceuticals reported positive preclinical toxicology results for aro-rage and aro-mmp7. The company reported fiscal q4 2023 results and provided a pipeline update this week. Shares of arrowhead dropped a quarter this week after fiscal q3 2023. Balance sheet concerns are weighing on the stock and the company needs to address them.
Seeking Alpha · 2d ago
Arrowhead Pharmaceuticals: Balancing Pipeline Progress and Financial Risks
TipRanks · 2d ago
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Titan machinery shares declined 8.1% to $23.41 on thursday. Minim inc shares jumped 700% after gaining over 13% on wednesday. Salesforce shares gained 8.4% after reporting strong third-quarter results. Redhill biopharma ltd. Shares fell 31% after the company reported weak quarterly results.
Benzinga · 3d ago
Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $37
Benzinga · 3d ago
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Benzinga · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Guardion Health Sciences (GHSI)
TipRanks · 3d ago
RBC Capital Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
TipRanks · 3d ago
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and efficient modes of delivery. The Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company's pipeline includes ARO-APOC3 for Hypertriglyceridemia; ARO-ANG3 for Dyslipidemia; Olpasiran for Cardiovascular disease; ARO-ENAC2 for Cystic fibrosis; ARO-MUC5AC and ARO-RAGE for Muco-obstructive or inflammatory pulmonary conditions; ARO-MMP7 for Idiopathic pulmonary fibrosis, and GSK-4532990 for Non-alcoholic steatohepatitis (NASH). It also offers Fazirsiran for lpha-1 antitrypsin deficiency (AATD); JNJ-3989 for Chronic hepatitis B virus; ARO-DUX4 for Facioscapulohumeral muscular dystrophy; HZN-457 for Uncontrolled gout; ARO-PNPLA3 for Non-alcoholic steatohepatitis, and ARO-SOD1 for Amyotrophic lateral sclerosis.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.